Asymchem (06821) Rises Nearly 3% Before Noon as Shanghai Fengxian Base Officially Commences Operations, Focusing on NDCs and Other Fields

Stock News12-08

Asymchem (06821) saw a nearly 3% increase before noon, reaching a 2.05% gain at the time of writing, with its stock price at HKD 79.65 and a trading volume of HKD 15.52 million.

The rise follows the recent announcement that Asymchem's Shanghai Fengxian commercial production base has officially commenced operations. This base is another core commercial facility for Asymchem Bio, following its Shanghai Jinshan base and Zhangjiang Science and Technology Center. It is designed to support clients in accelerating commercial production.

The launch of the Fengxian base marks a significant upgrade for Asymchem Bio in the biologics CDMO sector. The facility spans over 130,000 square meters and focuses on novel drug conjugates (NDCs), including antibody-drug conjugates (ADCs), as well as antibodies/TCEs and recombinant proteins.

The antibody commercial production capacity (Phase I-A) features advanced automation systems and equipment, with 200L/500L/2000L single-use bioreactor production lines and a 20㎡ lyophilizer, capable of handling IND and late-stage commercial projects.

The NDCs commercial production capacity (Phase I-B) is expected to begin operations in January 2026, equipped with 100L-200L-500L conjugation reactors and 10㎡+15㎡+2x20㎡ lyophilizers to flexibly meet client production demands.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173575743?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 11:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173575743","market":"fut","top_or_hot":-1,"title":"Asymchem (06821) Rises Nearly 3% Before Noon as Shanghai Fengxian Base Officially Commences Operations, Focusing on NDCs and Other Fields","media":"Stock News","content":"<p>Asymchem (06821) saw a nearly 3% increase before noon, reaching a 2.05% gain at the time of writing, with its stock price at HKD 79.65 and a trading volume of HKD 15.52 million.</p>\n<p>The rise follows the recent announcement that Asymchem's Shanghai Fengxian commercial production base has officially commenced operations. This base is another core commercial facility for Asymchem Bio, following its Shanghai Jinshan base and Zhangjiang Science and Technology Center. It is designed to support clients in accelerating commercial production.</p>\n<p>The launch of the Fengxian base marks a significant upgrade for Asymchem Bio in the biologics CDMO sector. The facility spans over 130,000 square meters and focuses on novel drug conjugates (NDCs), including antibody-drug conjugates (ADCs), as well as antibodies/TCEs and recombinant proteins.</p>\n<p>The antibody commercial production capacity (Phase I-A) features advanced automation systems and equipment, with 200L/500L/2000L single-use bioreactor production lines and a 20㎡ lyophilizer, capable of handling IND and late-stage commercial projects.</p>\n<p>The NDCs commercial production capacity (Phase I-B) is expected to begin operations in January 2026, equipped with 100L-200L-500L conjugation reactors and 10㎡+15㎡+2x20㎡ lyophilizers to flexibly meet client production demands.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asymchem (06821) Rises Nearly 3% Before Noon as Shanghai Fengxian Base Officially Commences Operations, Focusing on NDCs and Other Fields</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsymchem (06821) Rises Nearly 3% Before Noon as Shanghai Fengxian Base Officially Commences Operations, Focusing on NDCs and Other Fields\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 11:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Asymchem (06821) saw a nearly 3% increase before noon, reaching a 2.05% gain at the time of writing, with its stock price at HKD 79.65 and a trading volume of HKD 15.52 million.</p>\n<p>The rise follows the recent announcement that Asymchem's Shanghai Fengxian commercial production base has officially commenced operations. This base is another core commercial facility for Asymchem Bio, following its Shanghai Jinshan base and Zhangjiang Science and Technology Center. It is designed to support clients in accelerating commercial production.</p>\n<p>The launch of the Fengxian base marks a significant upgrade for Asymchem Bio in the biologics CDMO sector. The facility spans over 130,000 square meters and focuses on novel drug conjugates (NDCs), including antibody-drug conjugates (ADCs), as well as antibodies/TCEs and recombinant proteins.</p>\n<p>The antibody commercial production capacity (Phase I-A) features advanced automation systems and equipment, with 200L/500L/2000L single-use bioreactor production lines and a 20㎡ lyophilizer, capable of handling IND and late-stage commercial projects.</p>\n<p>The NDCs commercial production capacity (Phase I-B) is expected to begin operations in January 2026, equipped with 100L-200L-500L conjugation reactors and 10㎡+15㎡+2x20㎡ lyophilizers to flexibly meet client production demands.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1173575743","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173575743","pubTimestamp":1765165219,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Asymchem (06821) saw a nearly 3% increase before noon, reaching a 2.05% gain at the time of writing, with its stock price at HKD 79.65 and a trading volume of HKD 15.52 million. The rise follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06821":"凯莱英","BK0132":"高送转概念","002821":"凯莱英","BK0239":"医药制造","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1191":"制药"},"translate_title":"凯莱英(06821)午前涨近3%上海奉贤基地正式投产主攻NDC等领域","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1,"002821":1},"content_text":"Asymchem (06821) saw a nearly 3% increase before noon, reaching a 2.05% gain at the time of writing, with its stock price at HKD 79.65 and a trading volume of HKD 15.52 million.\nThe rise follows the recent announcement that Asymchem's Shanghai Fengxian commercial production base has officially commenced operations. This base is another core commercial facility for Asymchem Bio, following its Shanghai Jinshan base and Zhangjiang Science and Technology Center. It is designed to support clients in accelerating commercial production.\nThe launch of the Fengxian base marks a significant upgrade for Asymchem Bio in the biologics CDMO sector. The facility spans over 130,000 square meters and focuses on novel drug conjugates (NDCs), including antibody-drug conjugates (ADCs), as well as antibodies/TCEs and recombinant proteins.\nThe antibody commercial production capacity (Phase I-A) features advanced automation systems and equipment, with 200L/500L/2000L single-use bioreactor production lines and a 20㎡ lyophilizer, capable of handling IND and late-stage commercial projects.\nThe NDCs commercial production capacity (Phase I-B) is expected to begin operations in January 2026, equipped with 100L-200L-500L conjugation reactors and 10㎡+15㎡+2x20㎡ lyophilizers to flexibly meet client production demands.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173575743","isCrawlerRequest":true}